Skip to main content
Clinical Trials/NL-OMON38402
NL-OMON38402
Completed
Not Applicable

Prevention of recurrent urinary tract infections by multi-drug resistant bacteria, by intravesical administration of gentamicin. - SPRING

eids Universitair Medisch Centrum0 sites170 target enrollmentTBD

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Recurrent urinary tract infection
Sponsor
eids Universitair Medisch Centrum
Enrollment
170
Status
Completed
Last Updated
last year

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
last year
Study Type
Interventional

Investigators

Eligibility Criteria

Inclusion Criteria

  • 1\. Competent patient aged 18 or above.
  • 2\. A history of recurrent cystitis, defined as:
  • a. females: at least 2 episodes of UTI in the last 6 months or 3 in the last 12 months
  • b. males: at least 2 episodes of UTI in the last 12 months (including recurrent cystitis likely due to chronic bacterial prostatitis).
  • 3\. At least one episode of these infections is documented by urine culture with the isolation of \*10^3 CFU/mL of an identified MDR pathogen. Multidrug resistance is defined as acquired non\-susceptibility to at least one agent in three or more antimicrobial classes.
  • 4\. All other episodes at least by one urinary symptom\* and positive urinary nitrate test or leukocyturia (as depicted by positive leukocyte esterase test or microscopy).
  • 5\. No clinical symptoms of UTI at enrolment.

Exclusion Criteria

  • 1\. Urinary culture in prior 6 months tested positive for high\-level gentamicin resistant enterobacteriaceae or enterococci (MIC \>128 mg/L).
  • 2\. Abnormalities of the upper urinary tract, including presence of urinary stones.
  • 3\. Patients with a permanent urinary catheter.
  • 4\. Complete urinary incontinence.
  • 5\. Patients with stage 5 chronic kidney disease (GFR \<15 ml/min).
  • 6\. Patients with known hypersensitivity to gentamicin.
  • 7\. Pregnancy or lactation.
  • 8\. Inability to provide informed consent.

Outcomes

Primary Outcomes

Not specified

Similar Trials